Where I see patients (1)
My reviews
Selected research
-
Clinical efficacy of ONC201 in H3K27M-mutant diffuse midline gliomas is driven by disruption of integrated metabolic and epigenetic pathways.
Cancer discovery
-
A multicenter, phase 1, dose escalation clinical trial (G-FORCE-1) of XRT, RRx-001 and temozolomide followed by temozolomide +/- RRx-001 in newly diagnosed glioblastoma.
Frontiers in oncology
-
Targeting the IL4 receptor with MDNA55 in patients with recurrent glioblastoma: Results of a phase IIb trial.
Neuro-oncology
Clinical trials
Study of Sonodynamic Therapy Using SONALA-001 and Exablate 4000 Type 2 in Subjects With Progres...
Safety and tolerability of SONALA-001 SDT Definitions of Dose Limiting Toxicities (DLTs): The DLT window is the 21-day period following the first study treatment per patient. DLTs are defined as the following events during the DLT...
Recruiting
Contact me
- Request appointment
- Refer a patient
- (415) 353-2966
4.9